

Dexmedetomidine for mitral valve replacement

ACTRN12613000495729

Status	RECRUITING
Phase	Phase 3
Sponsor	south valley university -Qena university hospital
Enrollment	70 participants

Plain Language Summary

This study is testing a medication called dexmedetomidine to see if it can safely and effectively control heart rate in patients with severe mitral stenosis — a condition where the heart's mitral valve has narrowed significantly — before they undergo valve replacement surgery. Controlling heart rate during this time is important because it helps the heart pump blood more efficiently before the surgeon repairs the valve.

You may be eligible if:

- You are between 18 and 60 years old
- You have been diagnosed with tight (severe) mitral stenosis with a valve area less than 1 cm
- You are scheduled for mitral valve replacement surgery
- You are classified as low-to-moderate surgical risk (ASA I or II)

You may NOT be eligible if:

- You are under 18 or over 60 years old
- Your mitral valve area is greater than 1 cm
- You have kidney or liver problems
- You take heart medications that affect heart rate

Talk to your doctor about whether this trial might be right for you.

Key Eligibility Criteria

Inclusion (1)

- patients ASAI&II with tight (less than one centimeter) mitral stenosis aged 18-60 years of age scheduled for mitral valve replacement

Exclusion (1)

- age above or below 18-60 years , mitral valve area more than one centimeter, renal or hepatic dysfunction , cardiac medications that affect heart rate

Locations (1 total)

Qena - upper Egypt, Egypt

<https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12613000495729>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at anzctr.org.au. Generated by ClinicalTrialsFinder.org.